Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get trading ideas, historical data, advanced options screeners, more. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Amgen Inc (AMGN)

Amgen Inc (AMGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 134,310,480
  • Shares Outstanding, K 534,931
  • Annual Sales, $ 25,979 M
  • Annual Income, $ 5,893 M
  • 60-Month Beta 0.56
  • Price/Sales 5.11
  • Price/Cash Flow 10.51
  • Price/Book 54.85
Trade AMGN with:

Options Overview Details

View History
  • Implied Volatility 18.13% ( -0.36%)
  • Historical Volatility 13.76%
  • IV Percentile 1%
  • IV Rank 2.96%
  • IV High 30.77% on 04/26/22
  • IV Low 17.75% on 09/02/21
  • Put/Call Vol Ratio 0.14
  • Today's Volume 20,388
  • Volume Avg (30-Day) 7,603
  • Put/Call OI Ratio 0.88
  • Today's Open Interest 150,493
  • Open Int (30-Day) 152,544

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate 4.27
  • Number of Estimates 11
  • High Estimate 4.95
  • Low Estimate 1.91
  • Prior Year 4.67
  • Growth Rate Est. (year over year) -8.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
241.79 +4.70%
on 08/05/22
254.16 -0.40%
on 08/16/22
+4.46 (+1.79%)
since 07/15/22
3-Month
229.49 +10.31%
on 06/17/22
257.97 -1.87%
on 06/01/22
+9.28 (+3.81%)
since 05/16/22
52-Week
198.64 +27.44%
on 12/01/21
258.45 -2.05%
on 04/11/22
+22.08 (+9.56%)
since 08/16/21

Most Recent Stories

More News
5 Income Stocks to Turn to When Times Are Tough

The S&P 500 is coming off its four-week win streak amid signals of cooling price increases. However, inflation is still running hot near a 40-year high, which might induce the Fed to continue its policy...

ABBV : 142.55 (+0.18%)
AMGN : 253.15 (+0.82%)
BMY : 74.13 (-0.54%)
PFE : 49.86 (+0.22%)
SIRE : 21.93 (+0.55%)
Retail Scorecard and Analyst Reports for Coca-Cola, Oracle & Morgan Stanley

Today's Research Daily features update on the Q2 earnings season and new research reports on The Coca-Cola Company (KO), Oracle (ORCL) and Morgan Stanley (MS).

MS : 91.82 (-0.22%)
KO : 65.03 (+0.82%)
HON : 203.67 (+0.70%)
AMGN : 253.15 (+0.82%)
ORCL : 79.52 (+0.52%)
TTE : 52.65 (+1.52%)
5 Biotech Stocks in the Buy Zone This Week

The biotech industry is expected to see solid growth in the long term due to rising healthcare spending, breakthrough developments, and an aging population. Given the industry’s solid growth prospects...

AMGN : 253.15 (+0.82%)
BIIB : 219.64 (-1.23%)
GILD : 66.33 (+0.18%)
JAZZ : 158.72 (-0.96%)
VRTX : 303.00 (-0.83%)
Amgen (AMGN) is a Top-Ranked Value Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

AMGN : 253.15 (+0.82%)
Dogs of the Dow: 2 Stocks to Buy and 2 to Hold

The stock market has rebounded lately from the decline in the year's first half, thanks to better-than-expected corporate earnings and the expectation of easing inflationary pressure. However, a still...

AMGN : 253.15 (+0.82%)
MMM : 150.26 (-0.77%)
MRK : 90.59 (-0.01%)
VZ : 45.80 (+0.53%)
The Zacks Analyst Blog Highlights Amgen, ChemoCentryx, Mersana Therapeutics, GSK and Vertex Pharmaceuticals

Amgen, ChemoCentryx, Mersana Therapeutics, GSK and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.

GSK : 35.26 (+0.89%)
AMGN : 253.15 (+0.82%)
VRTX : 303.00 (-0.83%)
CCXI : 50.86 (+0.10%)
MRSN : 7.23 (-6.23%)
Biotech Stock Roundup: AMGN's Q2 Earnings, CCXI Acquisition & More Updates

Earnings updates from Amgen (AMGN) and its ChemoCentryx (CCXI) acquisition are a few key highlights from the biotech sector during the past week.

GSK : 35.26 (+0.89%)
AMGN : 253.15 (+0.82%)
VRTX : 303.00 (-0.83%)
CCXI : 50.86 (+0.10%)
MRSN : 7.23 (-6.23%)
AMGEN PRESENTS NEW TARLATAMAB CLINICAL DATA AT WCLC 2022

/PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new data from the DeLLphi300 clinical trial, a Phase 1 dose exploration and expansion study evaluating the...

AMGN : 253.15 (+0.82%)
Two Appealing Biotech Stocks for Two Distinct investors

Investing in biotech stocks carries both risk and reward. This article highlights two biotech companies that may appeal to specific investing styles

ABBV : 142.55 (+0.18%)
MRNA : 167.96 (-4.99%)
AMGN : 253.15 (+0.82%)
INO : 2.71 (-2.87%)
AMGEN DATA AT WCLC 2022 HIGHLIGHTS POTENTIAL TO DELIVER TRANSFORMATIVE MEDICINES FOR HISTORICALLY DIFFICULT-TO-TREAT LUNG CANCERS

/PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced three new data sets from its thoracic oncology portfolio that will be presented at the International...

AMGN : 253.15 (+0.82%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Amgen Inc. is the leading biotech companies world wide, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health & nephrology and neuroscience markets. It developed two most successful drugs, Epogen & Neupogen. Amgen successfully launched two...

See More

Key Turning Points

3rd Resistance Point 256.82
2nd Resistance Point 255.49
1st Resistance Point 254.32
Last Price 253.15
1st Support Level 251.82
2nd Support Level 250.49
3rd Support Level 249.32

See More

52-Week High 258.45
Last Price 253.15
Fibonacci 61.8% 235.60
Fibonacci 50% 228.55
Fibonacci 38.2% 221.49
52-Week Low 198.64

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar